Securities code: 000806 securities abbreviation: St Galaxy Announcement No.: 2021-115
Galaxy Biomedical Investment Co.Ltd(000806)
Application for retrial to the Supreme People’s court
Announcement of receipt of acceptance notice
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Important content tips:
● litigation stage of the case: retrial stage
● status of the listed company as a party: retrial applicant
● amount involved: 322 million yuan
● impact on Listed Companies: if the Supreme People’s court decides to retry, it may have a positive impact on the company
1、 Basic information of this lawsuit
On April 27, 2019, June 13, 2020, June 2, 2021 On November 20, 2021, it disclosed the case of Galaxy Biomedical Investment Co.Ltd(000806) (hereinafter referred to as “the company”), Sichuan Yongxing Electronics Co., Ltd. and Shanghai Zhuobo Industry Co., Ltd., Yinhe Tiancheng Group Co., Ltd., Yao Guoping, Pan Qi and pan Yong enterprise loan dispute on cninfo. For details, see the announcement on litigation progress disclosed by the company Announcement on the progress of litigation, announcement on the progress of litigation and related major risks, announcement on the progress of the original actual controller’s fund occupation and illegal guarantee (Announcement No.: 2019-021, 2020-056, 2021-068, 2021-110).
2、 Progress of application for retrial of this litigation case
The company applied to the Supreme People’s court for retrial on October 25, 2021. The retrial request is: 1 Request to revoke the Supreme People’s court’s (2020) Supreme faminzhong No. 935 civil judgment; 2. Request to revoke item 6 of Shanghai Higher People’s court’s (2018) HMC No. 99 civil judgment according to law, and change the judgment to reject Shanghai Zhuobo Industry Co., Ltd.’s claim against Galaxy Biomedical Investment Co.Ltd(000806) Beihai Galaxy Biological Industry Investment Co., Ltd. shall not bear the litigation expenses such as acceptance fee and preservation fee of the case.
Recently, the company received the notice of acceptance (2021) Supreme faminshen No. 7588) issued by the Supreme People’s court. The Supreme People’s court has filed and examined the retrial application of the company, Sichuan Yongxing Electronics Co., Ltd. and Shanghai Zhuobo Industrial Co., Ltd., Galaxy Tiancheng Group Co., Ltd., Yao Guoping, Pan Qi and pan Yong.
3、 The impact of this lawsuit on the company’s profits in the current period or after the period
The company has accrued an estimated liability of RMB 322 million for the litigation case according to the judgment of the second instance. If the Supreme People’s court decides to retry, it may have a positive impact on the company.
The company will perform the obligation of information disclosure in a timely manner in strict accordance with the requirements of relevant laws, regulations and normative documents according to the progress of the matter. The designated information disclosure media of the company are securities times, China Securities News, Shanghai Securities News, securities daily and cninfo (www.cn. Info. Com.. CN). The relevant information of the company shall be subject to the disclosure of the above designated media. Please pay attention to the investment risks.
It is hereby announced.
Galaxy Biomedical Investment Co.Ltd(000806) board of directors
December 23, 2001
